CO6251325A2 - Un anticuerpo humano o humanizado, o un fragmento del mismo con una region de enlace de antigeno que es especifica para dirigir la proteina al receptor de limfoproteina estromal timica humana (htslpr) - Google Patents

Un anticuerpo humano o humanizado, o un fragmento del mismo con una region de enlace de antigeno que es especifica para dirigir la proteina al receptor de limfoproteina estromal timica humana (htslpr)

Info

Publication number
CO6251325A2
CO6251325A2 CO09144825A CO09144825A CO6251325A2 CO 6251325 A2 CO6251325 A2 CO 6251325A2 CO 09144825 A CO09144825 A CO 09144825A CO 09144825 A CO09144825 A CO 09144825A CO 6251325 A2 CO6251325 A2 CO 6251325A2
Authority
CO
Colombia
Prior art keywords
seq
human
variable region
sequence
chain variable
Prior art date
Application number
CO09144825A
Other languages
English (en)
Inventor
Liqun Dong
Marc Nasoff
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of CO6251325A2 publication Critical patent/CO6251325A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/08Antibacterial agents for leprosy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1.- Un anticuerpo aislado o una porción de enlace de antígeno del mismo, el cual comprende una secuencia de la región variable de cadena pesada de la SEQ ID NO: 7 o de la SEQ ID NO: 21. 2.- Un anticuerpo aislado o una porción de enlace de antígeno del mismo, el cual comprende una secuencia de la región variable de cadena pesada de la SEQ ID NO: 7, y una secuencia de la región variable de cadena ligera de la SEQ ID NO: 8, o una secuencia de la región variable de cadena pesada de la SEQ ID NO: 21, y una secuencia de la región variable de cadena ligera de la SEQ ID NO: 22. 3.- El anticuerpo de la reivindicación 2, el cual comprende CDRH1, H2 y H3 de las SEQ ID NOs: 1, 2, y 3, respectivamente, o de las SEQ ID NOs: 15, 16, y 17, respectivamente, o una secuencia de CDRL1, L2 y L3 de las SEQ ID NOs: 4, 5, y 6, respectivamente, o de las SEQ ID NOs: 18, 19, y 20, respectivamente. 4.- El anticuerpo de la reivindicación 2, el cual comprende las CDRH1, H2 y H3 de las SEQ ID Nos: 1, 2, y 3, respectivamente, o de las SEQ ID Nos: 15, 16, y 17, respectivamente, y una secuencia de CDRL1, L2, y L3 de las SEQ ID NOs: 4, 5, y 6, respectivamente, o de las SEQ ID NO: 18, 19, y 20, respectivamente. 5.- El anticuerpo de la reivindicación 2, el cual comprende una secuencia de aminoácidos de la región variable de cadena pesada que es cuando menos el 80 por ciento idéntica a la SEQ ID NO: 7, y una secuencia de aminoácidos de la región variable de cadena ligera que es cuando menos el 80 por ciento idéntica a la SEQ ID NO: 8, o que comprende una secuencia de aminoácidos de la región variable de cadena pesada que es cuando menos el 80 por ciento idéntica a la SEQ ID NO: 21, y una secuencia de aminoácidos de la región variable de cadena ligera que es cuando menos el 80 por ciento idéntica a la SEQ ID NO: 22. 6.- El anticuerpo de la reivindicación 2, el cual es un anticuerpo quimérico.
CO09144825A 2007-06-20 2009-12-17 Un anticuerpo humano o humanizado, o un fragmento del mismo con una region de enlace de antigeno que es especifica para dirigir la proteina al receptor de limfoproteina estromal timica humana (htslpr) CO6251325A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94520507P 2007-06-20 2007-06-20

Publications (1)

Publication Number Publication Date
CO6251325A2 true CO6251325A2 (es) 2011-02-21

Family

ID=39846944

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09144825A CO6251325A2 (es) 2007-06-20 2009-12-17 Un anticuerpo humano o humanizado, o un fragmento del mismo con una region de enlace de antigeno que es especifica para dirigir la proteina al receptor de limfoproteina estromal timica humana (htslpr)

Country Status (20)

Country Link
US (1) US8101182B2 (es)
EP (1) EP2170957A1 (es)
JP (1) JP2010530233A (es)
KR (1) KR20100034015A (es)
CN (1) CN102027012A (es)
AR (1) AR067045A1 (es)
AU (1) AU2008265128A1 (es)
BR (1) BRPI0813725A2 (es)
CA (1) CA2691157A1 (es)
CL (1) CL2008001826A1 (es)
CO (1) CO6251325A2 (es)
CR (1) CR11152A (es)
EA (1) EA201000006A1 (es)
EC (1) ECSP099812A (es)
IL (1) IL202573A0 (es)
PE (1) PE20090768A1 (es)
TN (1) TN2009000529A1 (es)
TW (1) TW200918557A (es)
WO (1) WO2008155365A1 (es)
ZA (1) ZA200908711B (es)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4454859B2 (ja) 1998-11-13 2010-04-21 イミュネックス・コーポレーション ヒトtslpdnaおよびポリペプチド
DK1417231T3 (da) 2001-07-23 2013-07-22 Immunex Corp Modificeret human thymisk stromal lymphopoietin
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
AU2008287426B2 (en) * 2007-08-10 2014-06-26 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
JP2011511638A (ja) * 2008-02-07 2011-04-14 シェーリング コーポレイション 抗tslpr抗体の設計製作
AR082163A1 (es) * 2010-07-15 2012-11-14 Hoffmann La Roche Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos
KR101221649B1 (ko) * 2010-11-01 2013-01-14 광주과학기술원 알러지 질환의 예방 또는 치료용 약제학적 조성물, 그의 스크리닝 방법
JP6380394B2 (ja) 2013-08-09 2018-08-29 アステラス製薬株式会社 新規抗ヒトtslp受容体抗体
US10722655B2 (en) 2014-05-07 2020-07-28 Amgen Inc. Autoinjector with shock reducing elements
WO2015175861A1 (en) 2014-05-16 2015-11-19 Amgen Inc. Assay for detecting th1 and th2 cell populations
CN106470716B (zh) 2014-06-03 2020-07-17 安姆根有限公司 可控制药物递送系统和使用方法
CA2957960C (en) 2014-10-14 2023-08-22 Amgen, Inc. Drug injection device with visual and audible indicators
EA038462B1 (ru) 2014-10-23 2021-08-31 Эмджен Инк. Снижение вязкости фармацевтических составов
EP3233159B1 (en) 2014-12-19 2020-03-04 Amgen Inc. Drug delivery device with live button or user interface field
JP6484345B2 (ja) 2015-02-17 2019-03-20 アムジエン・インコーポレーテツド 固定及び/または戻りが真空によって支援された薬物送達装置
US11806509B2 (en) 2015-02-27 2023-11-07 Amgen Inc. Drug delivery device having a needle guard mechanism with a turnable threshold of resistance to needle guard movement
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
TN2018000076A1 (en) 2015-09-09 2019-07-08 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
CN108350070B (zh) 2015-09-09 2022-01-28 诺华股份有限公司 胸腺基质淋巴细胞生成素(tslp)-结合分子及该分子的使用方法
US11351308B2 (en) 2015-12-09 2022-06-07 Amgen Inc. Auto-injector with signaling cap
SG11201805123XA (en) 2015-12-18 2018-07-30 Astellas Pharma Inc Pharmaceutical composition comprising anti-human tslp receptor antibody
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
EP4035711A1 (en) 2016-03-15 2022-08-03 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
US11541168B2 (en) 2016-04-29 2023-01-03 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
US10988284B2 (en) 2016-05-13 2021-04-27 Amgen Inc. Vial sleeve assembly
EP3458988B1 (en) 2016-05-16 2023-10-18 Amgen Inc. Data encryption in medical devices with limited computational capability
EP3465124A1 (en) 2016-06-03 2019-04-10 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
EP3478342A1 (en) 2016-07-01 2019-05-08 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
US20200261643A1 (en) 2016-10-25 2020-08-20 Amgen Inc. On-body injector
AU2018210301A1 (en) 2017-01-17 2019-08-01 Amgen Inc. Injection devices and related methods of use and assembly
MX2019009625A (es) 2017-02-17 2019-10-09 Amgen Inc Dispositivo de administracion de farmacos con trayectoria de flujo de fluido esteril y metodo relacionado de ensamblaje.
US11369736B2 (en) 2017-02-17 2022-06-28 Amgen Inc. Cannula insertion and retraction mechanisms
WO2018165143A1 (en) 2017-03-06 2018-09-13 Amgen Inc. Drug delivery device with activation prevention feature
EP3592402A1 (en) 2017-03-07 2020-01-15 Amgen Inc. Needle insertion by overpressure
MX2019010671A (es) 2017-03-09 2019-10-21 Amgen Inc Mecanismo de insercion para dispositivo de administracion de farmacos.
BR112019020053B1 (pt) 2017-03-28 2023-10-10 Amgen Inc Máquina para acoplar uma haste de êmbolo a um conjunto de seringa e método de utilização da referida máquina
AU2018258676A1 (en) 2017-04-28 2019-10-31 Amgen Inc. N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides
US11904143B2 (en) 2017-06-08 2024-02-20 Amgen Inc. Torque driven drug delivery device
AU2018280054B2 (en) 2017-06-08 2023-07-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
CA3063920A1 (en) 2017-06-22 2018-12-27 Amgen Inc. Device activation impact/shock reduction
US11395880B2 (en) 2017-06-23 2022-07-26 Amgen Inc. Electronic drug delivery device
MA49562A (fr) 2017-07-14 2020-05-20 Amgen Inc Système d'insertion-rétractation d'aiguille présentant un système à ressort en double torsion
EP3655063A1 (en) 2017-07-21 2020-05-27 Amgen Inc. Gas permeable sealing member for drug container and methods of assembly
EP4085942A1 (en) 2017-07-25 2022-11-09 Amgen Inc. Drug delivery device with gear module and related method of assembly
US11484648B2 (en) 2017-07-25 2022-11-01 Amgen Inc. Drug delivery device with container access system and related method of assembly
JP7237022B2 (ja) 2017-08-01 2023-03-10 アムジエン・インコーポレーテツド 質量分析法による分析用ポリペプチド試料のリアルタイム調製のためのシステム及び方法
CA3071636A1 (en) 2017-08-01 2019-02-07 Amgen Inc. Systems and methods for performing a real-time glycan assay of a sample
MA49838A (fr) 2017-08-09 2020-06-17 Amgen Inc Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre
EP3668567A1 (en) 2017-08-18 2020-06-24 Amgen Inc. Wearable injector with sterile adhesive patch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
MA50611A (fr) 2017-10-04 2020-08-12 Amgen Inc Adaptateur d'écoulement destiné à un dispositif d'administration de médicament
WO2019070552A1 (en) 2017-10-06 2019-04-11 Amgen Inc. DRUG DELIVERY DEVICE COMPRISING A LOCKOUT ASSEMBLY AND ASSOCIATED ASSEMBLY METHOD
US11464903B2 (en) 2017-10-09 2022-10-11 Amgen Inc. Drug delivery device with drive assembly and related method of assembly
EP3703778A1 (en) 2017-11-03 2020-09-09 Amgen Inc. System and approaches for sterilizing a drug delivery device
CA3079197A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Drug delivery device with placement and flow sensing
US20200338271A1 (en) 2017-11-06 2020-10-29 Amgen Inc. Fill-finish assemblies and related methods
CN116832271A (zh) 2017-11-10 2023-10-03 安进公司 用于药物递送装置的柱塞
MX2020004996A (es) 2017-11-16 2020-08-27 Amgen Inc Un mecanismo de pestillo de puerta para un dispositivo de administracion de farmacos.
US20210255075A1 (en) 2018-03-13 2021-08-19 Amgen Inc. Sequential digestion of polypeptides for mass spectrometric analysis
WO2019178151A1 (en) 2018-03-13 2019-09-19 Amgen Inc. Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
KR20200004573A (ko) * 2018-07-04 2020-01-14 고려대학교 세종산학협력단 옥사졸로퀴놀리논 유도체를 유효성분으로 포함하는 우울증 및 스트레스 관련 질환의 예방 또는 치료용 약학 조성물
US20210260279A1 (en) 2018-07-24 2021-08-26 Amgen Inc. Hybrid drug delivery devices with optional grip portion and related method of preparation
MA53379A (fr) 2018-07-24 2021-06-02 Amgen Inc Dispositifs d'administration pour l'administration de médicaments
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
WO2020023451A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
US20210228797A1 (en) 2018-07-31 2021-07-29 Amgen Inc. Fluid path assembly for a drug delivery device
AU2019347710A1 (en) 2018-09-24 2021-02-04 Amgen Inc. Interventional dosing systems and methods
CA3110371A1 (en) 2018-09-28 2020-04-02 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
MA53815A (fr) 2018-10-02 2022-01-05 Amgen Inc Systèmes d'injection pour administration de médicament avec transmission de force interne
US20210338936A1 (en) 2018-10-05 2021-11-04 Amgen Inc. Drug delivery device having dose indicator
US20200114082A1 (en) 2018-10-15 2020-04-16 Amgen Inc. Drug delivery device having damping mechanism
TW202031306A (zh) 2018-10-15 2020-09-01 美商安進公司 用於藥物遞送裝置之平台組裝方法
WO2020091956A1 (en) 2018-11-01 2020-05-07 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
WO2020091981A1 (en) 2018-11-01 2020-05-07 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
TW202040117A (zh) 2018-12-14 2020-11-01 美商安進公司 與依照斜率的蛋白質濃度確定一起使用之系統適用性方法
EP3924083B1 (en) 2019-02-14 2024-05-15 Amgen Inc. Systems and methods for preparing a sample and performing a real-time assay of the sample
AU2020226619A1 (en) 2019-02-20 2021-08-05 Amgen Inc. Methods of determining protein stability
WO2020180967A1 (en) 2019-03-04 2020-09-10 Amgen Inc. In vivo reversibility of high molecular weight species
CA3133459A1 (en) 2019-03-27 2020-10-01 Amgen Inc. Methods of fingerprinting therapeutic proteins via a two-dimensional (2d) nuclear magnetic resonance technique at natural abundance for formulated biopharmaceutical products
AU2020263289A1 (en) 2019-04-24 2021-09-16 Amgen Inc. Syringe sterilization verification assemblies and methods
EP3981788A4 (en) 2019-06-04 2023-03-22 Jiangsu Hengrui Medicine Co., Ltd. ANTIBODY CAPABLE OF BINDING THYMIC STROMAL LYMPHOPOIETIN AND ITS USE
EP3980786A1 (en) 2019-06-05 2022-04-13 Amgen Inc. Methods of identifying attributes of therapeutic proteins
US20220273887A1 (en) 2019-08-23 2022-09-01 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
CN111171150B (zh) * 2020-02-05 2020-12-08 北京智仁美博生物科技有限公司 抗人tslp抗体及其用途
WO2022061092A1 (en) 2020-09-18 2022-03-24 Amgen Inc. Methods of processing a sample for peptide mapping analysis
MX2023005320A (es) 2020-11-05 2023-05-19 Amgen Inc Materiales y metodos para el procesamiento de proteinas.
EP4341161A1 (en) 2021-05-21 2024-03-27 Amgen Inc. Method of optimizing a filling recipe for a drug container
CA3237662A1 (en) 2021-11-09 2023-05-19 Amgen Inc. Production of therapeutic proteins

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69943022D1 (de) 1998-03-19 2011-01-20 Human Genome Sciences Rockville Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor
MXPA02012747A (es) * 2000-06-28 2003-09-25 Amgen Inc Moleculas del receptor de linfopoietina estromica timica y sus usos.
US6955895B2 (en) 2000-06-28 2005-10-18 Whitehead Institute For Biomedical Research Thymic stromal lymphopoietin receptor molecules and uses thereof
US6890734B2 (en) * 2000-11-10 2005-05-10 Schering Corporation Nucleic acids encoding a cytokine receptor complex
NZ533987A (en) * 2002-02-01 2007-04-27 Schering Corp Uses of mammalian cytokine; agonists and antagonists for modulating antigen presenting cell priming of T cells
JP5436753B2 (ja) * 2003-07-18 2014-03-05 メルク・シャープ・アンド・ドーム・コーポレーション 胸腺間質性リンホポエチンを使用する、新生物の処置および診断
US20050249712A1 (en) * 2004-03-23 2005-11-10 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for use of TSLP and agonists and antagonists thereof
EP1793856A2 (en) * 2004-08-20 2007-06-13 Amgen Inc. Methods and compositions for treating allergic inflammation
US20060171943A1 (en) 2005-02-01 2006-08-03 Amgen Inc. Compositions and methods of treating fibrotic disorders
CN101370831B (zh) 2006-01-13 2013-06-19 Irm责任有限公司 用于治疗过敏性疾病的针对胸腺基质淋巴细胞生成素受体的抗体
JP2011511638A (ja) 2008-02-07 2011-04-14 シェーリング コーポレイション 抗tslpr抗体の設計製作

Also Published As

Publication number Publication date
BRPI0813725A2 (pt) 2014-12-30
US20090074747A1 (en) 2009-03-19
TW200918557A (en) 2009-05-01
EA201000006A1 (ru) 2010-10-29
US8101182B2 (en) 2012-01-24
CA2691157A1 (en) 2008-12-24
IL202573A0 (en) 2011-08-01
ECSP099812A (es) 2010-01-29
WO2008155365A1 (en) 2008-12-24
TN2009000529A1 (en) 2011-03-31
CR11152A (es) 2010-01-20
JP2010530233A (ja) 2010-09-09
PE20090768A1 (es) 2009-07-09
AU2008265128A1 (en) 2008-12-24
CN102027012A (zh) 2011-04-20
ZA200908711B (en) 2010-08-25
EP2170957A1 (en) 2010-04-07
CL2008001826A1 (es) 2009-02-20
KR20100034015A (ko) 2010-03-31
AR067045A1 (es) 2009-09-30

Similar Documents

Publication Publication Date Title
CO6251325A2 (es) Un anticuerpo humano o humanizado, o un fragmento del mismo con una region de enlace de antigeno que es especifica para dirigir la proteina al receptor de limfoproteina estromal timica humana (htslpr)
CO6430469A2 (es) Anticuerpos humanizados que se unen a cd19 y sus usos
PE20110668A1 (es) Anticuerpos anti-linfopoyetina estromal timica (anti-tslp)
CR11030A (es) Proteinas de union, incluyendo anticuerpos, derivados de anticuerpos y fragmentos de anticuerpos, que se unen especificamente a cd154 y sus usos
CY1120414T1 (el) Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους
PE20140882A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
PE20110306A1 (es) Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3)
AR070346A1 (es) Anticuerpo especifico del receptor de linfopoyetina estromal timica (tslpr) y usos en trastornos inflamatorios e inflamatorios alergicos
AR083747A1 (es) Anticuerpos anti-il-23
PE20120340A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan
CR20130351A (es) Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina (diviisional 9819)
AR063090A1 (es) Proteinas de union al antigeno del receptor de la il-17
PE20120427A1 (es) Anticuerpos contra el receptor de cgrp humano
ES2572231T3 (es) Anticuerpos monoclonales anti-IL-21 humana
NZ700473A (en) Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
ES2572177T3 (es) Anticuerpos neutralizantes anti-B7RP1 humanos
AR095432A1 (es) Proteínas de unión a antígeno
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
EA201390146A1 (ru) Антитела к матриксной металлопротеиназе 9
PE20120429A1 (es) Proteinas de enlace de miostatina
PE20121361A1 (es) Antagonistas de pcsk9
PE20120414A1 (es) Proteinas biespecificas tetravalentes de union a antigeno
RS54113B1 (en) COMPOSITIONS AND PROCEDURES FOR ANTIBODIES ON THE C5 COMPLEMENTARY PROTEIN
PE20120306A1 (es) Anticuerpos anti-egfr y vectores que los codifican
PE20150222A1 (es) Anticuerpos multiespecificos

Legal Events

Date Code Title Description
FA Application withdrawn